Key points at a glance
- Tesamorelin is approved in several countries for reducing excess abdominal visceral fat in adults with HIV‑associated lipodystrophy. It is not a general weight‑loss medicine.
- Randomised trials show an average visceral adipose tissue (VAT) reduction of about 15–20% at ~26 weeks, with improvements maintained while treatment continues.
- Common side effects include injection‑site reactions, fluid retention, joint pain, carpal tunnel symptoms and increased IGF‑1. It can affect glucose tolerance and lipids, so monitoring is important.
- In Australia, tesamorelin access typically requires a qualified prescriber and may occur via TGA pathways such as the Special Access Scheme or Authorised Prescriber, where clinically appropriate.
What is HIV‑associated lipodystrophy?
HIV‑associated lipodystrophy refers to abnormal fat distribution that can occur in people living with HIV, often presenting as increased abdominal visceral fat (deep internal fat around organs). It can be metabolically active, contributing to insulin resistance, higher triglycerides and cardiovascular risk factors. The concern is not just appearance—excess VAT is linked to cardiometabolic risk.
How tesamorelin works
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). It stimulates the pituitary to release endogenous growth hormone (GH), which increases insulin‑like growth factor 1 (IGF‑1). This signalling can promote lipolysis in visceral fat depots and improve VAT volume when used in indicated patients with HIV‑associated lipodystrophy.
Importantly, tesamorelin targets visceral fat. It does not meaningfully increase limb or subcutaneous fat, and it is not intended for cosmetic fat reduction outside the approved indication.
Clinical evidence at a glance
- Several randomised, placebo‑controlled trials in adults with HIV on antiretroviral therapy demonstrated significant reductions in abdominal VAT (commonly measured by CT) with tesamorelin versus placebo over ~26 weeks, averaging about 15–20% VAT reduction in responders.
- Benefits tend to persist with continued therapy; VAT often rebounds toward baseline after discontinuation.
- Metabolic markers: studies report reductions in triglycerides and inflammatory markers in some patients, with small effects on other lipids. IGF‑1 rises as expected with GHRH stimulation.
- Liver health: in people with HIV and fatty liver disease, tesamorelin has been associated with reduced liver fat content and less progression of fibrosis markers in research settings.
- Quality of life and body image scores improved in some cohorts, aligning with reductions in central adiposity.
Outcomes vary by individual, baseline VAT, adherence and duration of use. Monitoring is essential to balance benefits with risks.
Who may be considered for tesamorelin
- Adults living with HIV on stable antiretroviral therapy who have clinically significant excess abdominal visceral fat consistent with lipodystrophy.
- Those with metabolic complications linked to VAT (e.g., insulin resistance, elevated triglycerides) where a clinician judges potential benefit.
Who may need caution or a different approach
- People with active or prior malignancy (GHRH/GH/IGF‑1 axis may be a consideration—specialist assessment required).
- Uncontrolled diabetes or significant insulin resistance without a monitoring plan.
- Pregnancy or breastfeeding.
- History of hypersensitivity to tesamorelin or excipients.
- Untreated pituitary disorders or unexplained elevated IGF‑1.
Side effects, warnings and interactions
Not everyone experiences side effects, but reported reactions include:
- Injection‑site reactions (redness, itching, pain), bruising
- Fluid retention (swelling), arthralgia, myalgia
- Numbness/tingling or carpal tunnel–type symptoms
- Headache, nausea
- Increases in IGF‑1
Metabolic considerations
- Glucose intolerance can occur; clinicians often monitor fasting glucose and HbA1c.
- Lipids may change; triglycerides can improve in some, but a lipid plan is advisable.
Other cautions
- Any new or recurrent neoplasms warrant immediate clinical review.
- Use only under medical supervision. This medicine is not for general weight loss or bodybuilding.
Monitoring and what to expect
- Baseline and periodic measures: waist circumference and, where available, imaging for VAT; fasting glucose/HbA1c; lipids; IGF‑1.
- Response is typically assessed at ~3–6 months. Benefit depends on ongoing use; VAT may return toward baseline if stopped.
- Lifestyle strategies (nutrition, physical activity, sleep) still matter for overall metabolic health and cardiovascular risk.
Access and legality in Australia
- Tesamorelin is a prescription‑only medicine. In Australia, access usually requires a qualified prescriber and may occur via TGA pathways such as the Special Access Scheme (SAS) or an Authorised Prescriber arrangement, when clinically appropriate.
- Avoid unregulated “research peptide” sellers. Importing or buying prescription medicines without a valid pathway can breach Australian law and exposes you to safety risks and product quality issues.
- Discuss eligibility, risks and monitoring with a clinician experienced in HIV care and metabolic complications.
Is tesamorelin legal in Australia? Peptide therapy in Australia: how access works Request help finding legitimate pathways
Alternatives and supportive strategies
- Reviewing antiretroviral therapy with your HIV specialist (modern regimens are generally more metabolically neutral than older agents).
- Targeted nutrition and exercise programs to reduce cardiometabolic risk regardless of tesamorelin use.
- Management of lipids, glucose and blood pressure per guidelines.
- Procedural options (e.g., liposuction) are not substitutes for addressing VAT‑related metabolic risk and should be discussed carefully with specialists.
Frequently asked questions
What does tesamorelin treat in HIV‑associated lipodystrophy?
It is used to reduce excess abdominal visceral adipose tissue (VAT) in adults with HIV on antiretroviral therapy.
How soon might results be noticed?
Trials measured meaningful VAT changes at around 26 weeks, with ongoing benefit while therapy continues. Individual timelines vary.
Does tesamorelin help with subcutaneous or limb fat?
It primarily targets visceral fat. It is not indicated to increase limb fat or for cosmetic fat reduction.
Will VAT return after stopping tesamorelin?
VAT tends to rebound toward baseline once treatment stops, which is why ongoing assessment is important.
Is tesamorelin a weight loss drug?
No. It is not for general weight loss. Its indication is specific to VAT reduction in HIV‑associated lipodystrophy.
What monitoring is recommended?
Glucose/HbA1c, lipids, IGF‑1, clinical exam and, where available, imaging for VAT. Your clinician will tailor a plan.
How do Australians access tesamorelin?
Through a qualified prescriber. Access may occur under TGA schemes such as SAS or Authorised Prescriber where clinically appropriate.
Where can I learn more?
See related pages below, or contact us for guidance.
Ask about tesamorelin for HIV lipodystrophy
Send a confidential message. We provide educational guidance and can help you navigate legitimate, clinician‑led pathways in Australia.
Prefer to read more first? Legal status in Australia · Dosage overview · How to read reviews
Summary
Tesamorelin targets visceral adiposity in HIV‑associated lipodystrophy, with clinical trials showing meaningful VAT reductions and potential metabolic benefits during therapy. Because it can raise IGF‑1 and affect glucose and lipids, clinician‑led care and regular monitoring are essential. Australians should seek lawful, supervised access pathways.